Fintel on MSN

Co-Diagnostics (CODX) price target increased by 2,900.00% to 38.25

The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $38.25 / share. This is an increase ...
Nasdaq

Quest Diagnostics Reaches Analyst Target Price

In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
Nasdaq

Bluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20

The average one-year price target for Bluejay Diagnostics (NASDAQ:BJDX) has been revised to 61.20 / share. This is an increase of 1,900.00% from the prior estimate of 3.06 dated July 5, 2023. The ...
Seeking Alpha

Lucid Diagnostics targets revenue growth with expanded sales initiatives and Medicare coverage prospects

CEO Lishan Aklog highlighted a strong close to 2024 and an optimistic start to 2025, driven by advancements in EsoGuard sales channels, reimbursement milestones, and increased clinical evidence. He ...
Investing

Lucid Diagnostics stock price target raised to $8.25 at Ascendiant Capital

Investing.com - Ascendiant Capital has raised its price target on Lucid Diagnostics Inc (NASDAQ:LUCD) to $8.25 from $8.00 while maintaining a Buy rating on the stock. This target represents a ...
Hosted on MSN

Quest Diagnostics price target raised to $210 from $190 at Mizuho

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $210 from $190 and keeps an Outperform rating on the shares as part of a Q3 earnings preview for the healthcare facilities and ...